BioCentury | May 22, 2018
Company News

Management tracks: Trevena, Galecto

...Diego, Calif.) hired Chris Mathes as chief commercial officer. He was chief commercial officer at Icagen...
BioCentury | Mar 31, 2017
Company News

Icagen, Bayer deal

...and Bayer partnered for up to two years to develop new X-ray fluorescence assays using Icagen’s...
...companies declined to disclose financial terms. XRpro allows for the high throughput assessment of transporters. Icagen...
...Research Triangle Park, N.C. Bayer AG (Xetra:BAYN), Leverkusen, Germany Business: High throughput screening Nora Weintraub Bayer AG Icagen...
BioCentury | Aug 10, 2015
Company News

Pfizer, XRpro deal

...obtained in its 2011 acquisition of Icagen Inc. The purchase includes Pfizer’s rights to the “Icagen”...
...Inc. The purchase includes Pfizer’s rights to the “Icagen” name and trademark. XRpro relaunched as Icagen...
...services. Pfizer scientists associated with the ion channel biology platform will transition to the new Icagen...
BioCentury | Apr 15, 2013
Company News

Icagen other research news

...of new channel isoforms is a goal, as is developing the company's drug screening capabilities. ICAgen...
BioCentury | Apr 15, 2013
Company News

Icagen, Bristol-Myers deal

...an ion channel thought to be specifically expressed in the atrial tissue of the heart. ICAgen...
...funding for two years, milestones, and royalties. The deal could be worth $75 million to ICAgen...
...Bristol-Myers will receive exclusive worldwide rights to lead compounds for the treatment of atrial fibrillation. ICAgen...
BioCentury | Apr 15, 2013
Company News

Icagen board of directors update

ICAgen Inc., Research Triangle Park, N.C. Business: Drug discovery Appointed: Dennis Gillings, Ph.D., chairman and CEO of Quintiles Transnational Corp. WIR Staff...
BioCentury | Mar 12, 2012
Company News

Viamet management update

...CFO, a newly created position, formerly EVP of finance and corporate development and CFO of Icagen...
BioCentury | Nov 7, 2011
Company News

Icagen, Pfizer deal

...Pfizer completed its acquisition of Icagen, which will become a wholly-owned subsidiary of Pfizer. Icagen will...
...unit for pain, sensory disorders and regenerative medicine (see BioCentury, July 25 & Sept. 26). Icagen...
BioCentury | Sep 26, 2011
Company News

Icagen, Pfizer deal

...Pfizer completed its subsequent tender offer to acquire the remaining shares of Icagen, acquiring 5.4 million...
...in a second-step merger, which is subject to Icagen shareholder approval (see BioCentury, Sept. 19). Icagen...
BioCentury | Sep 19, 2011
Company News

Icagen, Pfizer deal

...Pfizer extended for the final time its subsequent tender offer for the remaining shares of Icagen...
...completed its initial tender offer for Icagen, acquiring 4.6 million shares (see BioCentury, Sept. 12). Icagen...
Items per page:
1 - 10 of 170
BioCentury | May 22, 2018
Company News

Management tracks: Trevena, Galecto

...Diego, Calif.) hired Chris Mathes as chief commercial officer. He was chief commercial officer at Icagen...
BioCentury | Mar 31, 2017
Company News

Icagen, Bayer deal

...and Bayer partnered for up to two years to develop new X-ray fluorescence assays using Icagen’s...
...companies declined to disclose financial terms. XRpro allows for the high throughput assessment of transporters. Icagen...
...Research Triangle Park, N.C. Bayer AG (Xetra:BAYN), Leverkusen, Germany Business: High throughput screening Nora Weintraub Bayer AG Icagen...
BioCentury | Aug 10, 2015
Company News

Pfizer, XRpro deal

...obtained in its 2011 acquisition of Icagen Inc. The purchase includes Pfizer’s rights to the “Icagen”...
...Inc. The purchase includes Pfizer’s rights to the “Icagen” name and trademark. XRpro relaunched as Icagen...
...services. Pfizer scientists associated with the ion channel biology platform will transition to the new Icagen...
BioCentury | Apr 15, 2013
Company News

Icagen other research news

...of new channel isoforms is a goal, as is developing the company's drug screening capabilities. ICAgen...
BioCentury | Apr 15, 2013
Company News

Icagen, Bristol-Myers deal

...an ion channel thought to be specifically expressed in the atrial tissue of the heart. ICAgen...
...funding for two years, milestones, and royalties. The deal could be worth $75 million to ICAgen...
...Bristol-Myers will receive exclusive worldwide rights to lead compounds for the treatment of atrial fibrillation. ICAgen...
BioCentury | Apr 15, 2013
Company News

Icagen board of directors update

ICAgen Inc., Research Triangle Park, N.C. Business: Drug discovery Appointed: Dennis Gillings, Ph.D., chairman and CEO of Quintiles Transnational Corp. WIR Staff...
BioCentury | Mar 12, 2012
Company News

Viamet management update

...CFO, a newly created position, formerly EVP of finance and corporate development and CFO of Icagen...
BioCentury | Nov 7, 2011
Company News

Icagen, Pfizer deal

...Pfizer completed its acquisition of Icagen, which will become a wholly-owned subsidiary of Pfizer. Icagen will...
...unit for pain, sensory disorders and regenerative medicine (see BioCentury, July 25 & Sept. 26). Icagen...
BioCentury | Sep 26, 2011
Company News

Icagen, Pfizer deal

...Pfizer completed its subsequent tender offer to acquire the remaining shares of Icagen, acquiring 5.4 million...
...in a second-step merger, which is subject to Icagen shareholder approval (see BioCentury, Sept. 19). Icagen...
BioCentury | Sep 19, 2011
Company News

Icagen, Pfizer deal

...Pfizer extended for the final time its subsequent tender offer for the remaining shares of Icagen...
...completed its initial tender offer for Icagen, acquiring 4.6 million shares (see BioCentury, Sept. 12). Icagen...
Items per page:
1 - 10 of 170